Research article

Tumor necrosis factor (TNF) induces astrogliosis, microgliosis and promotes survival of cortical neurons

Ebtesam M Abd-El-Basset¹, Muddanna Sakkattu Rao¹,*; Solaiman M Alshawai²; Hasan Kh Ashkanani² and Abdulaziz H Kabli²

¹ Department of Anatomy, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13100, Kuwait
² MD students, Faculty of Medicine, Kuwait University, Kuwait

* Correspondence: Email: muddanna.rao@ku.edu.kw; Tel: 965-6570173, 965-24636279.

Abstract: Objectives: Neuro-inflammation occurs as a sequence of brain injury and is associated with production of cytokines. Cytokines can modulate the function and survival of neurons, microglia and astrocytes. The objective of this study is to examine the effect of TNF on the neurons, microglia and astrocytes in normal brain and stab wound brain injury. Methods: Normal BALB/c male mice (N) without any injury were subdivided into NA and NB groups. Another set mouse was subjected to stab wound brain injury (I) and were subdivided into IA and IB. NA and IA groups received intraperitoneal injections of TNF (1 µg/kg body weight/day) for nine days, whereas NB and IB groups received intraperitoneal injections of PBS. Animals were killed on 1st, 2nd, 3rd, 7th, and 9th day. Frozen brain sections through the injury site in IA and IB or corresponding region in NA and NB groups were stained for neurodegeneration, immunostained for astrocytes, microglia and neurons. Western blotting for GFAP and ELISA for BDNF were done from the tissues collected from all groups. Results: The number of degenerating neurons significantly decreased in TNF treated groups. There was a significant increase in the number of astrocytes and microglia in TNF treated groups compared to PBS treated groups. In addition, it was found that TNF stimulated the expression of GFAP and BDNF in NA and IA groups. Conclusions: TNF induces astrogliosis and microgliosis in normal and injured brain and promotes the survival of cortical neurons in stab wound brain injury, may be by upregulating the BDNF level.

Keywords: astrocytes; microglia; brain injury; TNF; cytokine
1. Introduction

Tumor necrosis factor (TNF) is a proinflammatory cytokine that regulates macrophage activity and involved in production of other pro-inflammatory cytokines, in addition to increasing prostaglandins and platelet activating factor. This suggests TNF’s central role in the development of inflammatory diseases [1–3]. TNF has also been linked with resolution of inflammation through LPS-mediated efferocytosis of neutrophils by macrophages mediated via TNF [4]. As such, many inflammatory diseases have used agents targeting TNF in treatment regiments, including rheumatoid arthritis, inflammatory bowel disease, psoriatic arthritis, ankylosing spondylitis, juvenile chronic arthritis, atherosclerosis, and sepsis [5–8]. In a clinical trial of arthritis induced neuropathic pain, anti TNF therapy showed success in relieving neuropathic pain. However, patients had a higher risk of developing adverse neurological diseases such as multiple sclerosis, optic neuritis, distal acquired demyelinating symmetric neuropathy [9–15].

TNF is expressed by many cells, including astrocytes and microglial cells of the brain. TNF has two types of receptors (TNFR1 and TNFR2) which are made up of four cysteine repeats. Both receptors are expressed in various tissues, with TNFR2 being more specific to the cells of the immune system [16,17]. The damaged brain contains high levels of TNF due to being released from microglia and astrocytes, after activation by pathogens or damage via pattern recognition receptors such as Toll-like receptors (TLRs) [18–20]. TNF has many roles in acute and chronic processes involving innate immunity, inflammation, infection, and pathogenesis of systemic and non-cerebral diseases [21].

Several studies have shown that TNF has a prominent role in the nervous system, however, these studies provide paradoxical roles of TNF, with some displaying a neuro-modulatory and protective effect in the normal or uninflamed brain. While others show a neurotoxic effect in the diseased or inflamed brain [22]. In the healthy CNS, TNF shows an important role in synaptic plasticity and modulating responses to neural injury [23,24] and regulating synaptic gliotransmission of astrocytes [25,26] as well as hippocampal homeostatic synaptic plasticity [27].

On the other hand, in pathological conditions, TNF is involved in the neuroinflammatory responses associated with various neurological disorders through de novo production of TNF by activated astrocytes and microglia [26,28]. Astrocytes and microglia are two main glial cells involved in neuroinflammation and progression of neurodegenerative disease [29]. Astrocyte are the most abundant glial sub type in the CNS [30] and their activation is associated with secretion of proinflammatory cytokines such as IL-1β and TNF [31,32]. Activated astrocytes have neuroprotective properties during inflammation through release of neurotrophic factors and maintaining the structural integrity of the blood brain barrier [33]. In addition, astrocytes have also shown the ability to interact and exert their control on microglia [34].

Research on hippocampal damage showed that increased TNF immunoreactivity in the hippocampus is associated with lower rates of survival in the early periods [35] suggesting the importance of further assessing crucial role of TNF in therapeutic strategies despite its known neurotoxic effects in various disease processes. The raising number of traumatic brain injuries (TBI) worldwide has led to an increased interest in research and awareness around the subject [36]. Understanding the mechanisms involved in the process of TBI, including inflammatory cytokines such as interleukin and TNF, helps us in predicting the prognosis, developing therapeutic strategies, as well as limiting the disability and mortality of the disease [37]. It is important to study the effects
of TNF on the brain to better understand its role in pathogenesis and in treatment of certain diseases involving the brain.

Thus, TNF released during inflammatory process or infused from external source has effects on neurons, neurotrophic factors, microglia and astrocytes in and around the injury site. In spared nerve injury (SNI) of the sciatic nerve, tumor necrosis factor is shown to be released and upregulated in bilateral hippocampus and ipsilateral spinal dorsal horn with significantly reduced dendrite lengths and spine densities in the hippocampus and increased in spinal cord neurokinin-1 positive neurons [38]. However, brain-derived neurotrophic factor (BDNF) is decreased in the hippocampus but increased in the ipsilateral spinal dorsal horn after SNI. These alternations were associated with microgliosis in both spinal dorsal horn and hippocampus and mediated through TNF receptor-1 [38]. Treatment with TNF promote gliosis and inflammatory response of activated Müller cells, thus aggravating retinal ganglion cells injury in glaucoma [39]. Large amount of TNF is released from microglia during inflammation stimulates astrogliosis. The elevations in TNF after neural injury precedes or occurs concomitantly with, the rise in glial fibrillary acidic protein mRNA, an early manifestation of astrogliosis [26]. A recent study showed the neuroprotective role of TNF-pretreatment in survival of human neural progenitor cells (hNPCs) in hypoxic-ischemic brain injury model [40].

Although the pro-inflammatory cytokine TNF is thought to be one of the major mediators of neuroinflammation, its role in brain injury, effects on neurons, microglia, astrocytes and trophic factors in and around the injury site remains ill-defined. TNF activity is very acute. It has been shown that TNF mRNA increases within 1 h in the ischemic injury core, and the expression of its immunoreactive protein increases within 2–6 h after the onset of ischemia in experimental models [41]. TNF increases in the serum of stroke patients as early as 6–12 h after symptom onset [38]. A recent study characterized the effect of acute exposure to low doses of TNF in a mouse hippocampal neuronal cell line (HT-22) and mouse primary cortical neurons. A rapid and significant mitochondrial dysfunction was observed after as little as 1.5 h of exposure to TNF which preceded cell death. This rapid action of TNF may be due to impairment of neuronal mitochondrial function [42]. In middle cerebral artery occlusion (MCAO), an experimental focal cerebral ischemia model, inhibition of microRNA-210 (miR-210) suppressed proinflammatory response and reduced brain damage in the acute phase of ischemic stroke. Further inhibition of miR-210 significantly reduced the expression of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) and chemokines (CCL2 and CCL3) but had no significant effect on anti-inflammatory factors (TGF-β and IL-10).

As stated above, TNF has both neuroprotective and neurodegenerative roles. It is well known that activated glial cells release inflammatory factors (including TNF) by themselves and damage neurons. What is not known fully is that weather extraneously infused TNF will provide neuroprotection or not in stab-wound injury. Our hypothesis is that extraneously infused TNF will have neuroprotection in stab-wound injury. It will stimulate astrocytes and microglia to secrete neurotrophic factor, which in turn protect the neurons from degeneration. Our hypothesis is based on a few literatures which indicated protective role of intrinsic TNF which was released from activated astroglia and microglia [39] and extraneous TNF on hNPCs [40]. Accordingly, the objective of this study is to examine the effect of TNF on the neurons, microglia and astrocytes in normal brain and stab wound brain injury in the cerebral cortical region.
2. Materials and methods

2.1. Animals

Two months old BALB/c male mice were used in the present study. Mice were maintained in the Animal Resources Centre, Faculty of Medicine, Kuwait University. Mice were fed with food and water ad-libitum. Animals were maintained in 12:12 dark: light cycle and room temperature were maintained at 25 ± 2 °C. The animal surgery, treatment protocol and maintenance were according to the approved protocol of the Institutional Animal Care and Use Committee of Kuwait University, which follows the recommendations of NIH Guidelines and the Guide for the Care and Use of Laboratory animals. A minimum and sufficient number of animals were used due to good experimental design and planning. Experiment that involved brain injury were performed on the animals under anesthesia, aseptic technique, and with the least harm inflicted to the animals. Ketamine (40 mg/kg)-xylazine (5 mg/kg) cocktail (ketamine hydrochloride/xylazine hydrochloride solution, Catalogue number: K4138, Sigma-Aldrich Inc., St. Louis, MO, USA) was used for anesthetizing the mice during stab-wound injury. Antiseptic betadine solution was applied on the skin wound after stab wound injury. All experimental protocols were approved by the institutional ethical committee as stated above.

2.2. Experimental animal groups, stab wound injury and treatment

This experiment was designed to investigate the role of TNF treatment on astrocytes and microglia, and neuronal survival in stab wound model of brain injury (an in vivo model of penetrating brain injury) and normal brain. A total of 264 BALB/c male mice were divided into two sets (n = 132/set). The first set of mice (N, normal mice) were not subjected to any injury and were subdivided into A (for TNF treatment, NA, n = 66) and B (for PBS treatment, NB, n = 66) groups. The second set mice were subjected to stab wound brain injury (I, injured mice). A stab wound was done on the cerebral cortex of these mice as described earlier [38]. Briefly, mice were anaesthetized with ketamine (40 mg/kg)-xylazine (5 mg/kg) mixture (Sigma Chemicals, St. Louis, USA), a stab-wound (penetrating brain injury) was made by inserting 21-gauge sterile needle into right frontal cerebral cortex following mouse brain atlas [43] [anteroposterior (AP) = 1.8 mm (in front of bregma), dorsoventral (DV) = 2 mm (from skull surface) and Lateral (L) = 3 mm (right side from midline)]. These injured mice were subdivided into A (TNF treatment, IA, n = 66) and B (PBS treatment, IB, n = 66) groups. NA and IA groups received intraperitoneal injections of TNF (1 µg/kg body wait/day) for nine days. First dose was given 1 hr after the stab-wound injury [44]. NB and IB groups received intraperitoneal injections of PBS (0.5 mL) for nine days, at a time matching with that of TNF treatment in NA and IA groups. Since TNF was dissolved in PBS, we used PBS as vehicle control. Animals were killed on 1st, 3rd and 7th days after the beginning of the experiment (n = 18 for each time point, in all groups: six for morphological study and six for western blot analysis of GFAP and six for ELISA analysis of BDNF). For BDNF analysis additional two time points 2nd and 9th day were used (n = 6 for each time point, in all groups). Frozen brain sections through the injury site in IA and IB or corresponding region in NA and NB groups were stained for Fluoro-Jade B (neurodegeneration), Immunostained of for GFAP (astrocyte marker), Iba-1 (microglia), and NeuN (neuronal marker). Morphological alterations are not as rapid as biochemical changes. Hence, we did morphological studies on 1st, 3rd and 7th day, excluding 2nd and 9th day time points. Western blotting (for GFAP) and
ELISA (for BDNF) were done from the tissues collected from the injury sites in IA and IB groups and corresponding site in NA and NB groups. BDNF analysis was done on the tissue collected on 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup>, 7<sup>th</sup> and 9<sup>th</sup> day (i.e. additional 2<sup>nd</sup> and 9<sup>th</sup> day groups for BDNF analysis). We wished to see BDNF level on 2<sup>nd</sup> day because alterations in levels of BDNF is quicker than morphological changes in the early post lesion days. We included 9<sup>th</sup> day in order to see the additional effect during two extended days (7<sup>th</sup> to 9<sup>th</sup>).

The number of mice used in different groups for morphological and biochemical studies were shown in Table 1. A total of 264 mice were used in the present study. Mice under morphological studies (N = 72) were equally distributed for each group for each time point of study (6 mice/group/time point of study) for Fluoro-jade B staining, Immunostaining for Astrocytes (GFAP), microglia (Iba1) and neurons (NeuN). Mice under biochemical studies (N = 192) were distributed 12 mice/group for 1<sup>st</sup>, 3<sup>rd</sup> and 7<sup>th</sup> day for analysis of BDNF by ELISA method (n = 6/group) and analysis of GFAP by western blot (n = 6/group), and 6 mice/group for 2<sup>nd</sup> and 9<sup>th</sup> day (for analysis of BDNF only by ELISA method (n = 6/group).

### Table 1. Number of mice used for morphological and biochemical studies.

| Groups | Morphological study-(FJB Staining, immunostaining for GFAP, Iba1, NeuN) | Biochemical studies-(ELISA for BDNF and Western Blot for GFAP) | Total |
|--------|-------------------------------------------------|-------------------------------------------------|-------|
|        | Day | 1<sup>st</sup> | 3<sup>rd</sup> | 7<sup>th</sup> | Day | 1<sup>st</sup> | 2<sup>nd</sup> | 3<sup>rd</sup> | 7<sup>th</sup> | 9<sup>th</sup> |
| IA     |     | 6     | 6     | 6     |     | 12    | 6     | 12    | 12    | 6     | 66    |
| IB     |     | 6     | 6     | 6     |     | 12    | 6     | 12    | 12    | 6     | 66    |
| NA     |     | 6     | 6     | 6     |     | 12    | 6     | 12    | 12    | 6     | 66    |
| NB     |     | 6     | 6     | 6     |     | 12    | 6     | 12    | 12    | 6     | 66    |
| Total  |     | 24    | 24    | 24    |     | 48    | 24    | 48    | 48    | 24    | 264   |

### 2.3. Tissue fixation and sectioning

The animals were perfused transcardially with saline followed by 4% paraformaldehyde (Catalogue no. 158127, Sigma-Aldrich Inc., St. Louis, MO, USA) and their brains were dissected and fixed in 4% paraformaldehyde for 48 hours. Then brains were cryoprotected in 10%, 20%, and 30% sucrose solution as described before [45]. Thirty-micron, thick serial, coronal frozen sections were cut and collected in 24 well culture plates filled with phosphate buffer.

### 2.4. Fluoro Jade B (FJ-B) staining

To visualize degenerating neurons, the brain sections from non-injured and injured brains were processed for FJ-B histochemical staining. Fluoro-Jade B and C are an anionic fluorescein derivative useful for the histological staining of neurons undergoing degeneration. Fluoro-Jade B has a greater...
specific affinity for degenerating neurons than Fluoro-Jade B. We used FJ-B for staining the degenerating neurons around injury site.

The brain sections were mounted on gelatin coated slides and air dried at room temperature overnight. Slides were rehydrated and treated with 0.06% potassium permanganate followed by washing in distilled water. The sections were then treated with 0.004% FJ-B (Catalogue no. MFCD04974901, Fluoro-Jade B, Histo-Chem Inc., Jefferson, Arkansas, 72079, USA) in 0.1% acetic acid for 30 minutes with slow shaking in dark. The sections were rinsed in distilled water, dehydrated and mounted with DPX. Number of FJ-B stained degenerating neurons were counted in six randomly selected photograph/section taken around the injury site (n = 6/group in each time point) (Photographs were taken with 40x objective in an olympus fluorescence microscope). Finally, the number of degenerating neurons/mm³ tissue were calculated for each mouse as detailed below.

2.5. Immunostaining for astrocytes (GFAP), microglia (Iba-1) and neurons (NeuN)

The brain sections were treated with 3% hydrogen peroxide, then with 5% normal goat serum for 30 minutes. The sections were incubated with polyclonal rabbit anti-GFAP (1:100, Catalogue no. ab7260, Abcam Inc., Cambridge, United Kingdom, CB2 0AX), polyclonal rabbit anti-Iba-1 (1:500, Catalogue no. ab153696, Abcam Inc., Cambridge, United Kingdom, CB2 0AX) or mouse monoclonal anti-NeuN (1:1000, Catalogue no. ab104224, Abcam Inc., Cambridge, United Kingdom, CB2 0AX) antibody overnight at 4 °C. Glial fibrillary acidic protein (GFAP) is an intermediate filament protein of 52 kD found in glial cells such as astrocytes. We used anti-GFAP antibody for immunostaining astrocytes for identification of astrocytes around the injury site and for immunoblotting for GFAP in western blot analysis of GFAP content in the tissue around the injury site. Ionized calcium binding adaptor molecule 1 (IBA1), is a marker of microglia/macrophages. It is a 17-kDa protein that is specifically expressed in macrophages/microglia and is upregulated during the activation of these cells. Iba1 expression is up-regulated in microglia following nerve injury, central nervous system ischemia, and several other brain diseases. We used anti-Iba1 antibody for immunostaining astrocytes for identification of activated microglia around the injury site. NeuN (neuronal nuclei) antibodies are fundamental tools for staining mature neurons and studying neuronal development and differentiation. We used anti-NeuN antibody to immunostaining to identify the mature neurons around the injury site. The sections were then incubated with biotinylated goat anti-rabbit IgG (1:200, Catalogue no. BA-1000, Vector Labs, Burlingame, CA, USA) or biotinylated horse anti mouse IgG (1:200, Catalogue no. BA-2000, Vector Labs, Burlingame, CA, USA) for 1 hour at room temperature. All sections were treated with ExtrAvidin peroxidase (1:20, Catalogue no. E2886, Sigma-Aldrich Inc., St. Louis, MO, USA) for 1 hour. The color was developed using DAB solution (Catalogue no. SK-4100, Vector Labs, Burlingame, CA, USA). Then the sections were dehydrated in ascending grades of ethyl alcohol, cleared in xylene and mounted with DPX.

2.6. Quantification of degenerating neurons and immunostained neurons, astrocytes and microglia

Number of degenerating neurons, immunostained neurons, astrocytes and microglia were quantified as described earlier [45]. Six photomicrographs were taken from each sections around the lesion site in stab-wound injury site in stab-wound injured mice or corresponding region in non-injury mice (Photographs were taken with 40x objective). Number of Fluoro-Jade B stained degenerating
neurons, NeuN positive neurons, GFAP stained astrocytes and Iba-1 stained microglia were counted in these six randomly selected field photographs. From each mouse six sections (60 µm apart) were selected for quantification. Finally, number of FJ-B stained degenerating neurons, NeuN positive neurons, astrocytes or microglia/mm³ tissue were calculated for each mouse as described earlier [45]. Briefly, total number of degenerating neurons, neurons, astrocytes or microglia/mm³ tissue were quantified by using the data collected from a total of 36 sections/mice (n = 6/group) using the formula: T = (N × V)/t, where N is the numerical cell density, V is the volume of the lesioned tissue around the lesion site used for quantification and t is section thickness (30 µm). The numerical cell density (N) was calculated by using the area of the section used for quantification, area of each field used for quantification and total cell counts in six randomly selected fields. NIS-Elements software (NIS-Elements-D2.20) was used for area measurement. The volume (V) was calculated by multiplying the area of section with section thickness (30 µm), inter-section distance (60 µm) and number of sections used (6 sections).

2.7. Polyacrylamide gel electrophoresis (PAGE) and immunoblotting

Animals were perfused with 50 mL of cold saline. Tissue around the injury site (5 mm³) and from corresponding regions of non-injury brains were removed and snap frozen in liquid nitrogen and stored at −80 °C until Western Blot analysis as described earlier [46]. Briefly, tissue was thawed and incubated in ice cold radioimmunoprecipitation assay (RIPA) lysis buffer [Catalogue no. sc-24948, Santa Cruz Biotechnology, Inc., Dallas, Texas 75220, USA; with sodium orthovanadate (0.5 mM), and the protease inhibitors, phenylmethanesulfonyl fluoride (PMSF; 1 mM), aprotinin (10 µg/ml), leupeptin (1 µg/ml)] for 10 minutes. Tissue was homogenized in cold, in a tissue homogenizer for 3–5 minutes, homogenate was centrifuged at 14,000 rpm at 4 °C for 5 min to collect the supernatant. The protein concentration in the samples was determined using a spectrophotometer. All samples (75 µg protein/well) were analyzed electrophoretically on a 10% SDS-PAGE gel [46]. The proteins in the gel were transferred to nitrocellulose membrane [47]. After transfer, the membranes were incubated for 1 h with 5% skim milk in Tris-buffered saline-Tween 20 (TBST). The immunoblots were probed with rabbit anti-GFAP (Catalogue no. ab7260, Abcam Inc., Cambridge, United Kingdom, CB 2 0AX) diluted in 5% skimmed milk in Tris-buffered saline-Tween 20 (TBST). The immunoblots were probed with rabbit anti-GFAP (Catalogue no. ab7260, Abcam Inc., Cambridge, United Kingdom, CB 2 0AX) diluted in 5% skimmed milk in Tris-buffered saline-Tween 20 (TBST), and rabbit anti-Glyceradehde-3-phosphate dehydrogenase (GAPDH, Catalogue no. SAB1410512, Sigma Aldrich Inc., St. Louis, MO, USA) were used as endogenous sample loading control. This was then followed by incubation with affinity-purified goat anti-rabbit conjugated to horse-radish peroxidase (1:100, Catalogue no. 401353, Sigma-Aldrich, St. Louis, MO, USA). Immunoreactive bands were visualized using enhanced chemiluminescence system (ECL, Catalogue no. sc-2048, Santa Cruz Biotechnology, Inc., Dallas, Texas, USA). The difference in the band intensities on exposed films were determined by densitometric scanning. Intensity of bands were quantified in the Image-J image analysis software.

2.8. ELISA for BDNF

Tissue samples (5 mm³ tissue around injury site) were collected snap frozen in liquid nitrogen, stored at (−80 °C) and were weighed immediately to get the wet weight of the samples and analyzed for BDNF content as described earlier [45]. Brain-derived neurotrophic factor is a protein (Molecular Weight of mature BDNF: 14 kDa). In humans, it is encoded by the BDNF gene. BDNF is a member
of the neurotrophin family of growth factors, which are related to the canonical nerve growth factor. We used the ChemiKine Brain Derived Neurotrophic Factor, Sandwich ELISA kit for analysis of BDNF content in the tissue around the injury site. ELISA plates pre-coated with anti-BDNF antibodies were used for analysis of BDNF in the tissue. Each sample was transferred to 250 µL of ice-cold homogenization buffer and homogenized for one minute in a tissue homogenizer. Composition of the homogenization buffer was 100 mM Tris/HCl, pH 7, 2% bovine serum albumin (BSA), 1 M NaCl, 4 mM EDTA, Na2, 2% Triton X-100, 0.1% sodium azide and the protease inhibitors (5 µg/mL aprotinin, 0.5 µg/mL antipain, 157 µg/mL benzamidine, 0.1 µg/mL pepstatin A and 17 µg/mL phenylmethyl-sulphonyl fluoride). The lysate from each sample was centrifuged at 14,000 revolutions/minute (rpm) for 30 min at 4 °C and the supernatant solutions were collected. The supernatant from each sample was frozen for subsequent measurements of BDNF by using ChemiKine brain derived neurotrophic factor (BDNF) sandwich ELISA kit (Catalogue no. CYT306, Merck Millipore, Billerica MA, USA) following the protocol provided in the kit. Briefly 100 µL of standards or appropriately diluted samples were added into each flat bottom wells, pre-coated with mouse anti-Human BDNF monoclonal antibody and incubated at 4 °C overnight on a shaker. Wells were washed three times with 250 µL of diluted wash buffer. 100 µL of the diluted biotinylated mouse anti-BDNF monoclonal antibody (1:1000 in sample diluent) was added to each well and incubated at room temperature for three hours on a shaker. Wells were washed again three times with 250 µL of diluted wash buffer. 100 µL of the diluted streptavidin-HRP conjugate solution (1:1000, in sample diluent) was added to each well and incubated at room temperature for one hour on a shaker. Wells were washed three times with 250 µL of diluted wash buffer. 100 µL of TMB substrate (3, 3’, 5, 5’-tetramethylbenzidine) was added to each well and incubated at room temperature for 15 minutes. Reaction was stopped by adding 100 µL of stop solution to each well. The wells were read immediately in an ELISA plate reader at 450 nm. Optical density of standard solution was plotted against known concentration of the standards to get the standard curve. Unknown concentration of the BDNF in the samples were calculated by plotting their OD values into the standard curve.

2.9. Statistical analysis

Number FJ-B positive degenerating neurons, NeuN stained normal neurons, number of GFAP stained astrocytes, Iba-1 stained microglia, were counted in six randomly selected fields in each section around the injury sites and corresponding area from non-injury area. From each mouse six sections (60 µm apart) were selected for quantification. Six mice were used in each group. Finally, mean number of astrocytes or microglia or degenerating neurons or neurons/mm³ tissue were calculated as described above. The data were expressed as Mean ± SEM and were analyzed by two-tailed Student’s t-test or Two-way ANOVA, followed by Bonferroni’s post-test. p-values < 0.05 was considered statistically significant.

3. Results

In all mice with stab-wound injury, tip of the needle remained in the frontal cortical region. It did not injure any other nuclei or structures (striatum, thalamic nuclei or hippocampus).
3.1. Effect of TNF on neurons around the injury site

Figure 1. (A) Photomicrographs showing Fluro Jade B stained degenerating neurons (arrows) around the stab-wound injury site in injured mice treated with TNF (IA) and injured mice treated with PBS (IB) on 1st, 3rd and 7th day. As there are no degenerating neurons stained by Flurojade-B in non-injured mice brain sections [both treated with TNF (NA) and PBS (NB)], those photographs were not included. Note the decreased distribution of the degenerating neurons in TNF treated mice (IA) compared to PBS treated mice (IB) at all-time points. Scale bar = 60 μm. (B) Graph showing the number of degenerating neurons on 1st, 3rd and 7th day in injured mice treated with TNF (IA, n = 6 for each time point) and injured mice treated with PBS (IB, n = 6 for each time point). Note the significantly decreased number of degenerating neurons in TNF treated mice compared to PBS treated mice on 1st day (Student’s t-test, **** p < 0.0001), 3rd day (*** p < 0.001) and 7th day (**** p < 0.0001). Also note that in both IA and IB degenerating neurons progressively decreased from 1st day to 3rd day (aa p < 0.01) and 3rd day to 7th day (bb p < 0.01). Since there were no FJ-B stained neurons in non-injured groups (NA and NB), there is no quantified data shown in the graph.
Figure 2. (A) Photomicrographs of the brain section from stab wound injured mice showing NeuN immunopositive neurons in TNF treated mice (IA) and PBS treated mice (IB) on 1st, 3rd and 7th day. Note the presence of many neurons in the TNF treated mice (IA, indicating less neuronal degeneration) compared to PBS treated mice (IB) at all-time points. Scale bar = 50 μm. (B) Graph showing the number of NeuN immunopositive neurons in TNF (IA, n = 6 for each time point) and PBS (IB, n = 6 for each time point) treated mice on 1st, 3rd and 7th day. Note significantly more number of neurons in TNF treated mice compared to PBS treated mice at 3rd (Student’s t-test, *** p < 0.001) and 7th day (**** p < 0.0001). Also note that in IA group number of neurons progressively increased from 1st day to 3rd day (a p < 0.05) and 3rd day to 7th day (bb p < 0.01), but not in IB group. Since there was no difference in the number of NeuN positive neurons in non-injured mice treated with TNF (NA), and treated with PBS (NB), those photographs and data were not shown.

Flouro Jade B (FJ-B) staining revealed degenerating neurons around the injury site in the stab wound brain injury. Distribution of degenerating neurons in injured mice treated with TNF was less
dense compared to injured mice treated with PBS at 1st, 3rd and 7th post injury days (Figure 1A). FJ-B staining on non-injured and treated with TNF (Group-NA) and treated with PBS (Group-NB) did not show any FJ-B stained neurons at all-time points of the study (Photographs and data are not shown). Quantification of FJ-B stained degenerating neurons showed significant decrease in the number of degenerating neurons in injured mice treated with TNF compared to injured mice treated with PBS at all post injury days studied (1st Post injury day: Student’s t-test, p < 0.0001, Welch’s approximate t = 8.538 with 6 degrees of freedom; 3rd post injury day: Student’s t-test, p = 0.0003, Welch’s approximate t = 6.102 with 8 degrees of freedom; and 7th post injury day: Student’s t-test, p < 0.0001, Welch’s approximate t = 9.839 with 7 degrees of freedom; Figure 1B). There was progressive decrease in the number of degenerating neurons from 1st day to 3rd day (p < 0.01) and 3rd day to 7th day (p < 0.01, Figure 1B).

Immunostaining of sections from injured brain with anti-NeuN antibody for neurons showed denser distribution of neurons around the injury site in injured mice treated with TNF compared to injured mice treated with PBS at 3rd and 7th post injury days (Figure 2A). Immunostaining of sections from non-injured brain treated with TNF (Group-NA) and treated with PBS (Group-NB) with anti-NeuN antibody did not show any difference at all-time points studied (Photograph and data are not shown). Quantification of the NeuN positive neurons around the injury site showed significantly more number of neurons in injured mice treated with TNF compared to injured mice treated with PBS at 3rd and 7th post injury day (Student’s t-test, 3rd day: p < 0.001, Welch’s approximate t = 4.71 with 8 degrees of freedom; 7th day: p < 0.0001, Welch’s approximate t = 7.307 with 10 degrees of freedom, Figure 2B) indicating decreased neurodegeneration in mice treated with TNF. Quantification and comparison of neurons in non-injured brain treated with TNF (Group-NA) compared to non-injured mice treated with PBS (Group-NB) at all-time points studied did not show any difference (Data not shown). In injured and treated with TNF (IA group) number of neurons progressively increased from 1st day to 3rd day (p < 0.05) and 3rd day to 7th day (p < 0.05), but not in injured and treated with PBS (IB group).

3.2. Effect of TNF on astrocytes around the injury site

Brain sections immunostained for GFAP, showed an increase in the distribution of astrocytes in non-injured mice treated with TNF to a smaller extent and in injured mice treated with TNF-α treated to a greater extent on 3rd and 7th day compared to non-injured and injured mice treated with PBS (Figure 3A and 3B). Quantification of the number of astrocytes around the injury site showed a significant increase in both non-injured and injured treated with TNF at 3rd and 7th day compared to respective PBS treated mice (Figure 4, One-way ANOVA, Bonferroni multiple comparison test—3rd day: IA vs IB, p < 0.001, NA vs NB, p < 0.001, F = 74.52, df = 3,20; 7th day: IA vs IB, p < 0.001, NA vs NB, p < 0.001, F = 283.92, df = 3,20). In both non-injured brain and injured brain treated with TNF, increase in the astrocytes was significant and progressive from 1st day to 3rd day (p < 0.05) and 3rd day to 7th day (p < 0.05) (Figure 4). However, such a progressive increase in the number of astrocytes is not seen in non-injured groups treated with TNF or PBS (NA and NB).
Figure 3. (A) Photomicrographs showing glial fibrillary acidic protein (GFAP) immunostaining (arrows) in the brain section of non-injured mice treated with TNF (NA) and mice treated with PBS (IB) at 1\textsuperscript{st}, 3\textsuperscript{rd} and 7\textsuperscript{th} day. Note the increase in the distribution of astrocytes in non-injured and treated with TNF (NA) mice at 3\textsuperscript{rd} and 7\textsuperscript{th} day compared to non-injured and treated with PBS (IB). Scale bar = 50 μm. (B) Photomicrographs showing glial fibrillary acidic protein (GFAP) immunostaining (arrows) in the brain section of injured mice treated with TNF (IA) and injured mice treated with PBS (IB) at 1\textsuperscript{st}, 3\textsuperscript{rd} and 7\textsuperscript{th} day. Note the increase in the density of astrocytes distribution in injured and treated with TNF (IA) mice at 3\textsuperscript{rd} and 7\textsuperscript{th} day compared to injured and treated with PBS (IB). Scale bar = 50 μm.
Figure 4. Graph showing the number of astrocytes at 1st, 3rd and 7th days in stab wound injured mice treated with TNF (IA, n = 6 for each time point) or treated PBS (IB, n = 6 for each time point) and age matched non-injured mice treated with TNF (NA, n = 6 for each time point) or treated with PBS (NB, n = 6 for each time point). Note significantly increased number of astrocytes in injured mice treated with TNF (IA) compared injured mice treated with PBS (IB) at 3rd (One-way ANOVA, Bonferroni multiple comparison test, IA vs IB, *** p < 0.001) and 7th (IA vs IB, *** p < 0.001) day. Similarly, note significantly increased number of astrocytes in non-injured mice, treated with TNF (NA) compared non-injured mice treated with PBS (NB) at 3rd day (NA vs NB, ### p < 0.001) and 7th day (NA vs NB, ### p < 0.001). Further also note that in both IA and IB number of astrocytes progressively increased from 1st day to 3rd day (a p < 0.05) and 3rd day to 7th day (b p < 0.05). However, such a progressive increase in the number of astrocytes is not seen in non-injured groups treated with TNF or PBS (NA and NB).

Western blot analysis for GFAP showed significantly enhanced GFAP content in both non-injured (Figure 5A, B) and injured mice (Figure 5C, D) treated with TNF compared to PBS-treated group on 3rd and 7th post injury days [Student’s t-test, Non-injured groups (3rd day: NA vs NB, p < 0.001, t = 11.25, df = 6; 7th day: NA vs NB, p < 0.0001, t = 31.11, df = 6, Figure 5A, B); Injured groups (3rd day: IA vs IB, p < 0.001, t = 28.39, df = 6; 7th day: NA vs NB, p < 0.0001, t = 25.65, df = 6, Figure 5C, D)]. Further the GFAP contents significantly increased from 1st day to 3rd day (p < 0.01) and 3rd day to 7th day (p < 0.01) in injured mice treated with TNF (3rd day vs 7th day, p < 0.001). However, such a progressive increase in the GFAP content was not seen in non-injured groups treated with TNF (NA) or PBS (NB).
Figure 5. (A) Glial fibrillary acidic protein (GFAP) immunoblotting from 1st, 3rd and 7th day tissues from non-injured mice treated with TNF (NA, n = 6 for each time point) and non-injured mice treated with PBS (NB, n = 6 for each time point) probed with anti-GFAP and anti-GAPDH antibodies. (B) Graph showing the mean grey value (GFAP/GAPDH) of the immunoblots. Note significantly increased GFAP content in NA compared to NB at 3rd (Student’s t-test, *** p < 0.001) and 7th days (*** p < 0.001). (C) Glial fibrillary acidic protein (GFAP) immunoblotting from 1st, 3rd and 7th day tissues from injured mice treated with TNF (IA, n = 6 for each time point) and injured mice treated with PBS (IB, n = 6 for each time point) probed with anti-GFAP and anti-GAPDH antibodies. (D) Graph showing the mean grey value (GFAP/GAPDH) of the immunoblots. Note significantly increased GFAP content in IA compared to IB at 3rd day (*** p < 0.001) and 7th day (**** p < 0.0001). Further note that GFAP contents significantly increased from 1st day to 3rd day (aa p < 0.01) and 3rd day to 7th day (bb p < 0.01) in injured mice treated with TNF. However, such a progressive increase in the GFAP content is not seen in non-injured groups treated with TNF (NA) or PBS (NB).
Figure 6. (A) Photomicrographs showing ionized calcium binding adaptor molecule-1 (Iba1) immunostaining in brain sections from non-injured mice treated with TNF (NA) and non-injured mice treated with PBS (NB) at 1st, 3rd and 7th day. Note the increase in the microglia distribution in non-injured mice treated with TNF (NA) compared to non-injured mice treated with PBS (NB) at 3rd and 7th day. Scale bar = 50 μm. (B) Photomicrographs showing ionized calcium binding adaptor molecule-1 (Iba1) immunostaining in brain sections from injured mice treated with TNF (IA) and injured mice treated with PBS (IB) at 1st, 3rd and 7th day. Note the increase in the microglia distribution in injured mice treated with TNF (IA) compared to injured mice treated with PBS (IB) at 1st, 3rd and 7th day. Scale bar = 50 μm.

3.3. Effect of TNF on microglia around the injury site

Brain sections immunostained with Iba-1 showed increased density microglial distribution in both non-injured and injured mice treated with TNF on 1st, 3rd and 7th day (Figure 6A and 6B). Quantification of the microglia around the injury site showed significant increase in the number of microglia in both non-injured and injured mice treated with TNF compared to PBS treated
mice (Figure 7) (One-way ANOVA, Bonferroni multiple comparison test: 1st day: IA vs IB, p < 0.001, F = 37.35, df = 3,20; 3rd day: IA vs IB, p < 0.001, NA vs NB, p < 0.001, F = 42.07, df = 3,20; 7th day: IA vs IB, p < 0.001, NA vs NB, p < 0.001, F = 164.54, df = 3,20; Figure 7). Further, the number of microglia significantly increased from 1st day to 3rd day (a p < 0.05) and 3rd day to 7th day (b p < 0.05) in injured mice treated with TNF and PBS. However, such a progressive increase in the microglia is not seen in non-injured groups treated with TNF (NA) or PBS (NB).

**Figure 7.** Graph showing the number of microglia at 1st, 3rd and 7th days in stab wound injured mice treated with TNF (IA, n = 6 for each time point), stab wound injured mice treated PBS (IB, n = 6 for each time point), age matched non-injured mice treated with TNF (NA, n = 6 for each time point) and age matched non-injured mice treated with PBS (NB, n = 6 for each time point). Note significantly increased number of microglia in injured mice treated with TNF (IA) compared to injured mice treated with PBS (IB) at 1st day (One-way ANOVA, Bonferroni multiple comparison test, IA vs IB, *** p < 0.001), 3rd day (IA vs IB, *** p < 0.001) and 7th day (IA vs IB, *** p < 0.001). Similarly, note significantly increased number of microglia in non-injured mice treated with TNF (NA) compared non-injured mice treated with PBS (NB) at 3rd day (NA vs NB, ### p < 0.001) and 7th day (NA vs NB, ### p < 0.001). Further, note that number of microglia significantly increased from 1st day to 3rd day (a p < 0.05) and 3rd day to 7th day (b p < 0.05) in injured mouse treated with TNF. However, such a progressive increase in the microglia is not seen in non-injured groups treated with TNF (NA) or PBS (NB).

3.4. Effect of TNF on expression of BDNF around the injury site

BDNF level was significantly increased in non-injured and injured mice treated with TNF compared to mice treated with PBS at all-time points studied (Figure 8; One-way ANOVA, Bonferroni multiple comparison test: 1st day: IA vs IB, p < 0.001, NA vs NB, p < 0.001, F = 910.67, df = 3,20; 2nd day: IA vs IB, p < 0.001, NA vs NB, p < 0.001, F = 809.17, df = 3,20; 3rd day: IA vs IB, p < 0.001, NA vs NB, p < 0.001, F = 1262.1, df = 3,20; 7th day: IA vs IB, p < 0.001, NA vs NB, p < 0.001, F = 2424.7, df = 3,20; 9th day: IA vs IB, p < 0.001, NA vs NB, p < 0.001, F = 2943.9, df = 3,20). Increase in the BDNF concentration in the tissue around the injury site was progressive from day-1 to day-9. The BDNF content significantly increased from 1st day to 9th day (1st day vs 9th day: p < 0.01) in
injured mouse treated with both TNF and PBS. However, such a progressive increase in the GFAP content is not seen in non-injured groups treated with TNF (NA) or PBS (NB).

**Figure 8.** Graph showing the concentration of BDNF on 1st, 2nd, 3rd, 7th and 9th day in the tissue around the injury site in the stab wound injured mice treated with TNF (IA, \( n = 6 \) for each time point), stab wound injured mice treated with PBS (IB, \( n = 6 \) for each time point), non-injured mice treated with TNF (NA, \( n = 6 \) for each time point), and non-injured treated with PBS (NB, \( n = 6 \) for each time point). Note significantly increased BDNF content in injured mice treated with TNF (IA) compared injured mice treated with PBS (IB) at all-time points (One-way ANOVA, Bonferroni multiple comparison test, IA vs IB, *** \( p < 0.001 \)). Similarly, note significantly increased BDNF content in non-injured mice treated with TNF (NA) compared non-injured mice treated with PBS (NB) at all-time points (One-way ANOVA, Bonferroni multiple comparison test, NA vs NB, ### \( p < 0.001 \)). Further note that BDNF content significantly increased from 1st day to 9th day (1st day vs 9th day: cc \( p < 0.01 \)) in injured mouse treated with both TNF and PBS. However, such a progressive increase in the BDNF content is not seen in non-injured groups treated with TNF (NA) or PBS (NB).

### 4. Discussion

In this study, we have demonstrated activation of the astrocytes (astrogliosis) and microglia (microgliosis) in brains of both normal mice (non-injury) and stab wound injured mice treated with TNF for 1, 3 or 7 days. We observed decreased neurodegeneration (alternatively neuroprotection) in stab wound injured mice that are treated with TNF for 3 or 7 days compared to injured mice that are treated with vehicle. Neurodegeneration decreased progressively from 1st day to 3rd day and 3rd day to 7th day in stab-wound injured and treated with TNF as well as in those treated with PBS. Further the BDNF content in the tissue around the injury site in stab-wound injured + TNF treated (treated for 1, 2, 3, 7 and 9 days) mice was significantly increased. The observed neuroprotection may be related to glio-stimulatory role of extraneously infused TNF, where in TNF stimulated both astrocytes and microglia to become activated. These activated glial cells might have
AIMS Neuroscience

Volume 8, Issue 4, 558–584.

released neurotrophic factor BDNF, which in-turn protected the neurons from degeneration in the stab-wound injury. Our results are consistent with a previous study with similar conclusions [48] and the role of other cytokines IL-1β and IFN-γ in astrogliosis, microgliosis and neuronal protections in stab wound injury [49].

4.1. TNF neurotoxicity in stab wound neurodegeneration

We observed degenerating neurons, especially on the first day, in and around the injury site in injured mice treated with both PBS and TNF. This initial neurodegeneration may be due to several toxic substances released from the injured cells and may be due to toxicity of TNF itself (from infused and/or intrinsic TNF). It is proposed that TNF not only has neuroprotective role, it also plays a negative role in the nervous system. It has been shown that high level of TNF is associated with the progression of a variety of neurological disorders, including Alzheimer’s disease, as well as Parkinson’s disease [50,51].

Neurodegeneration also may be due to localized activation of neuroinflammation by TNF, which could initiate neuronal death, even though TNF has not been demonstrated to cause neuronal death in healthy brain [52]. In an animal model of cerebral ischemia, a dramatic up-regulation of TNF protein and mRNA has been shown [53,54]. TNF expression has been shown to increase preceding the onset of neuronal cell death [41]. In an in-vitro model of neurodegenerative disease, it was confirmed that pro-inflammatory cytokines interleukin-1β (IL-1β) and TNF are elevated in the neurodegenerative disease state and induced neuronal death and apoptosis [55].

The observed neurodegeneration in our study also may be through activation of microglia, indeed our results showed increased microglia in the injured brain. Although it is assumed that microglia are the major source of TNF during neuroinflammation [56], even astrocytes and neurons produce TNF [57].

During neuroinflammation, different inflammatory stimuli activate microglia and activate several signaling pathways (p38MAPK, NF-κB) [58,59]. TNF de novo production and release during the neuroinflammatory process, is mediated by infiltrated CD4+ and CD8+ T cells. These cells release the IFN-γ which, via the MEK/ERK signaling pathway, induce microglia for increased de novo TNF production and release.

The mechanism of TNF neurotoxicity is claimed to be through release of excessive glutamate. TNF can potentiate cytotoxicity by (i) inhibiting glutamate transport on astrocytes and by rapidly triggering the expression AMPA and NMDA receptors, (ii) decreasing inhibitory GABA receptors on neurons [26]. Thus, excessive TNF harms the central nervous system and the harmful effect is through release of excessive glutamate. It is well known that when extracellular glutamate accumulates, it inhibits synaptic activity or kills the neurons and associated synapses as well [60].

Neurodegeneration observed in our study may be mediated through TNF’s TNFR1 receptor which activates the caspase family, which induce cell death. Involvement of TNFR1 in neurodegeneration in stab-wound injury needs to be explored in future studies. TNF acts through its two receptors TNFR1 and TNFR2. Both receptors are expressed in various tissues, with TNFR2 being more specific to the cells of the immune system [61]. TNFR1 is ubiquitously expressed on nearly all cells. TNFR2 is restricted to T lymphocytes and other cells [62]. TNFR2 is expressed by cells of myeloid lineage, peripheral T cells and alveolar lymphocytes and macrophages [63]. TNFR2 is limited in both its expression and its activation. Expression of TNFR2 is restricted to cell types, including
endothelial cells, fibroblasts and subsets of neurons and immune cells (myeloid cells, T- and B-cell subsets) [64,65].

4.2. Role of TNF in neuroprotection in stab wound injury

Our results showed a neuroprotection by TNF in the stab-wound injury. It may be through neurotrophic factors released from activated astrocytes and/or microglial cells. Alternatively, it may be direct beneficial effect of TNF as it is claimed to be neuroprotective also. TNF is a pro-inflammatory cytokine that regulates several biological processes, including apoptosis, differentiation, proliferation, as well as activation of neurons [66]. TNF regulates inflammation when released at very low levels [67]. TNF has also been linked with resolution of inflammation [4]. Peripherally derived TNF can exert its effect through the HPA axis and the vagus nerve to stimulate various CNS responses, such as neuroendocrine responses, sleep and fever, and immune system regulation [68]. Peripherally infused TNF can act directly on the brain by entering the CNS through the blood brain barrier (BBB) either by active transport mechanisms or passive diffusion [68,69]. This proves the crucial role of TNF in normal brain physiology. Above studies are in support of our hypothesis that, extraneously infused TNF may act on the nervous system. In healthy CNS, TNF is released at very low levels by a variety of brain cells including neurons [67]. TNF, in addition to having neuroprotective role, shows an important role in synaptic plasticity [23,24]. Recent studies indicate that there is a neuroprotective and function-maintaining role for TNF, and TNF is essential in maintaining synaptic plasticity, as well as learning and memory formation [70]. In a study conducted on mice, it was found that mice with absent TNF or deleted TNF-receptors displayed significantly poor learning and impaired cognitive function, which shows that low levels of TNF under non-inflammatory immune conditions is important for normal cognitive function [71].

4.3. Role of TNF in Astrogliosis in stab-wound injury

Our results showed astrogliosis in both normal and injured mice treated with TNF. X. Hu et al. showed enhancement of GFAP in the normal Muller’s glial cell to a smaller extent and to a larger extent in preactivated Muller glial cells by treatment with TNF [39]. Marked increase in the levels of TNF and also transcripts for interleukin (IL)-1a, IL-1b was reported in a nitrocellulose membrane stab injury model in the adult mouse. This elevation of TNF was associated with the increase in glial fibrillary acidic protein mRNA, an early manifestation of astrogliosis, an observation consistent with our study [72,73]. Astrocytes play major role in neuroinflammation. They are the regulators of immune responses (innate and adaptive) in the injured neural tissue. Astrocyte activity may enhance the inflammatory reactions and tissue damage or facilitate immunosuppression and tissue repair depending on timing and context [74]. Experiments show that the loss of gliosis during the early phases of injury results in exacerbation and persistence of inflammatory cells. Astrocytes depletion during the chronic phase of experimental autoimmune encephalomyelitis (EAE) ameliorates disease and reduces leukocyte infiltration into the CNS [75,76].

Several other studies also indicate a strong association between TNF and astrocytes in in neural injury/lesion models, which are comparable to our stab-wound injury models. Exposure of astrocytes in tri-culture medium (medium formulated to support neurons, astrocytes, and microglia) to LPS (Lipopolysaccharides) hypertrophies the astrocytes, increases the secretion of a number
of pro-inflammatory cytokines (e.g. TNF, IL-1α, IL-1β, and IL-6). Following mechanical trauma in the tri-culture showed increased astrocyte migration towards the site of injury. Microglia in the tri-culture plays a significant neuroprotective role during glutamate-induced excitotoxicity [77]. Above literature are in agreement with our argument that extraneously infused TNF, along with intrinsic TNF released from cells in and around injury site stimulate astroglial cells to become activated, which in-turn play their role in neuroprotection. Significant increase in number of astrocytes and GFAP content at 3rd and 7th in stab wound injured and treated with TNF compared with PBS treated groups suggest the gliosis under the influence of infused TNF. The TNF stimulatory effect is sustained as there was a significant increase from 3rd day to 7th day in both groups treated with TNF and PBS. This may be due to combined action of intrinsic and infused TNF. The enhancement of astrocytes to a smaller extent in injured and treated with PBS may be due to action of intrinsic TNF released from the activated astrocytes, microglia or both.

4.4. Role of TNF in Microgliosis in stab-wound injury

Microglia exhibit both beneficial and detrimental effects in neuroinflammation. Results of our study showed enhanced number of microglial cells in the injured brain treated with TNF at 3rd and 7th post injury days compared to that injured and treated with PBS. Activated microglia produce protective factors that help to prevent neuronal injury, such as BDNF, glial cell-derived neurotrophic factor (GDNF) and nerve growth factor (NGF) [77,78]. In our study we have shown enhancement of BDNF in TNF treated group, which is consistent with the earlier reports [79,80]. However, we have not studied other neurotrophic factors. There is a need for analyzing the other neurotrophic factors and their role in stab-wound injury.

Microglia, when activated stimulate an adaptive immune response. They release several inflammatory mediators like proinflammatory cytokines, chemokines, prostaglandins, inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), free radicals [81]. Purpose of such reactions are for the repair and the restoration of the homeostasis. However, it may also lead to complications, resulting in tissue injury [82]. In our study we have not addressed the question whether such inflammatory mediators are released from the activated microglial cells and astrocytes. It is likely that, activated microglial cells release such mediators as reported by others, and tend to aggravate the inflammation. However, it appears that even though such mediators are released they are not at high levels, as we observed neuroprotection rather than neurodegeneration. Further studies on these inflammatory mediators in stab-wound injury is required.

Activation of microglial receptors (P2X4Rs) leads to increased levels of BDNF [79]. Activated microglia also produce pro-inflammatory cytokines which tend to increase the inflammation [80]. Microglia release large amounts of TNF during inflammation, an important component of the neuroinflammatory reaction. Microglia have shown an important role in mechanisms of neuropathic pain following neurodegeneration through purinergic signaling, especially through expression of P2X and P2Y receptors (P2XR and P2YR) [83]. Activation of microglial P2X4Rs shown to increase the levels of BDNF [83]. BDNF reported to alter transmembrane anion gradient in subpopulations of lamina-1 neurons in the spinal cord dorsal horn by downregulating the neuronal chloride transporter KCC2, contributing to neuropathic pain [84].

Above literature on microglia agree with our argument that extraneously infused TNF, along with intrinsic TNF released from cells in and around injury site stimulate microglial cells to become
activated, which in turn play their role in neuroprotection. Significant increase in number of microglia at 1st, 3rd and 7th day in stab wound injured and treated with TNF compared with PBS treated groups suggest the gliosis under the influence of infused TNF. The TNF stimulatory effect on microglia appears to be sustained as there was a significant increase from 1st day to 3rd day and 3rd day to 7th day in both groups treated with TNF and PBS. This may be due to combined action of intrinsic and infused TNF. The enhancement of microglia to a smaller extent in injured and treated with PBS may be due to action of intrinsic TNF released from the activated astrocytes, microglia or both.

4.5. Role of BDNF in neuronal survival in stab wound injury

Our results showed a positive correlation between increased BDNF release and enhanced survival of neurons in mice that are injured and treated with TNF. Studies indicate the physiological relationship between BDNF and astrocytes [85]. Studies on injured adult spinal cord showed that BDNF increased dramatically compared to normal, non-injured spinal cord, and it was associated with enhanced neuron survival and axon regeneration, an observation consistent with our study. Binding of BDNF into its receptor TrkB, activates several pathways and induces the expression of genes related to neuronal proliferation, survival, and inflammatory response [86]. Studies have shown that binding of BDNF into its other receptor, p75NTR, increases apoptotic and inflammatory signaling in neurons and glial cells [75,76]. Recent studies suggest that BDNF may also be a potential target for new treatment strategies. In animal models of neurodegenerative diseases, therapy with BDNF in vivo and in vitro showed promising results [87]. Neurogenesis and regional neuronal activity increased after BDNF infusion into the hippocampus of adult rats [88]. Previous studies indicate the physiological relationship between BDNF and astrocytes [80]. In addition, other studies on injured adult spinal cord showed that BDNF increased dramatically compared to normal, non-injured spinal cord, and it was associated with enhanced neuron survival and axon regeneration [89].

As discussed above, in our study activated astrocytes and microglia after treatment with TNF may be responsible for increased release of BDNF as well as neuronal protection. However, we have not addressed the question on the source of BDNF, weather it is from activated astrocyte or activated microglia or both. Further studies are required to address this question.

Significant increase in BDNF contents at all-time points studied in stab wound injured and treated with TNF compared with PBS treated groups may be the key factor in neuroprotection. The TNF’s sustained stimulatory effect on microglia and astrocytes might have caused sustained and a significant increase in BDNF from 1st day to 9th day in both groups treated with TNF and PBS. This may be due to combined action of intrinsic and infused TNF. The enhancement of BDNF to a smaller extent in injured and treated with PBS may be due to action of intrinsic TNF released from the activated astrocytes, microglia.

Thus, TNF has both neuroprotective and neurodegenerative effects. TNF is produced both in the normal tissue and injured tissue. The neuroinflammatory process is associated with activation of microglia, astrocytes and release of the TNF and BDNF. Being a pro-inflammatory cytokine, TNF when it is in excess, aggravates further gliosis and inflammation. When TNF is at its moderate level, it facilitates resolving of inflammation and hence neuroprotection. The BDNF, released from activated microglia and astrocytes counteract aggravation of inflammation induced by excessive TNF. It is hard to determine whether the observed effects (gliosis and neuroprotection), in our study are from the extraneous infused TNF or both intrinsic and extrinsic source. It may be the combined effect of both.
intrinsic and extrinsic source. The receptor through which it mediates its effects needs to be studied. Similarly, BDNF may be from activated astrocytes, microglia or both, which needs to be determined in future studies.

5. Conclusions

This study indicates that TNF activates astrocytes (astrogliosis) and microglia in normal brain (non-injury) and stab wound injury. TNF protects the cortical neurons and decreases their degeneration in stab wound injury. This neuroprotection may be through enhancement of BDNF. Enhancement of BDNF probably by either by activated astrocytes or activated microglia or both. Further experiments are needed to find weather activated astrocyte or microglia or both play their role in enhancement of BDNF or any other mechanisms exist. Results of our study is promising to use TNF as therapeutic agent to treat neural injuries and neurodegenerative diseases, however several additional experiments are needed to validate a few things such as to know the different dose effects of TNF, adverse effects of extraneously infused TNF, to find the source of BDNF (weather from astrocyte or microglia). This study supports strategies of preserving the activating astrocytes and microglia in the planning of future therapies to promote regeneration in brain injury.

Acknowledgements

This work was supported by the Kuwait University and OMICS RU under Grant (Number-CSRUL02/13). Authors would like to acknowledge Animal Resources Centre (ARC) for providing mice and animal house facility. We also thank Mrs Amna Najem for her technical assistance.

Conflict of interest

All authors declare no conflicts of interest.

References

1. Maini RN, Elliott MJ, Brennan FM, et al. (1995) Beneficial effects of tumor necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA). *Clin Exp Immunol* 101: 207–212.
2. Vassalli P (1992) The pathophysiology of tumor necrosis factors. *Annu Rev Immunol* 10: 411–452.
3. Clark IA (2007) How TNF was recognized as a key mechanism of disease. *Cytokine Growth Factor Rev* 18: 335–343.
4. Michlewiska S, Dransfield I, Megson IL, et al. (2009) Macrophage phagocytosis of apoptotic neutrophils is critically regulated by the opposing actions of pro-inflammatory and anti-inflammatory agents: key role for TNF-alpha. *FASEB J* 23: 844–854.
5. Feldmann M, Brennan FM, Elliott MJ, et al. (1995) TNF alpha is an effective therapeutic target for rheumatoid arthritis. *Ann N Y Acad Sci* 766: 272–278.
6. Kollias G, Douni E, Kassiotis G, et al. (1999) On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. *Immunol Rev* 169: 175–194.
7. Beutler B, Cerami A (1989) The biology of cachectin/TNF—a primary mediator of the host response. *Annu Rev Immunol* 7: 625–655.

8. Kleemann R, Zadelaar S, Kooistra T (2008) Cytokines and atherosclerosis: a comprehensive review of studies in mice. *Cardiovasc Res* 79: 360–376.

9. Mohan N, Edwards ET, Cupps TR, et al. (2001) Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritis. *Arthritis Rheum* 44: 2862–2869.

10. Shin IS, Baer AN, Kwon HJ, et al. (2006) Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. *Arthritis Rheum* 54: 1429–1434.

11. Fromont A, Binquet C, Clerc L, et al. (2009) Epidemiology of multiple sclerosis: The special situation in France. *Rev Neurol (Paris)* 165: 671–675.

12. Fernández-Espartero MC, Pérez-Zafrilla B, Naranjo A, et al. (2011) Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. *Semin Arthritis Rheum* 40: 330–337.

13. Seror R, Richez C, Sordet C, et al. (2013) Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. *Rheumatology (Oxford)* 52: 868–874.

14. Kaltsonoudis E, Zikou AK, Voulgari PV, et al. (2014) Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. *Arthritis Res Ther* 16: R125.

15. Liu W, Wu YH, Zhang L, et al. (2016) Efficacy and safety of TNF-α inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis. *Sci Rep* 6: 32768.

16. Banner DW, D’Arcy A, Janes W, et al. (1993) Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. *Cell* 73: 431–445.

17. Pfeffer K, Matsuyama T, Kundig TM, et al. (1993) Mice deficient for the 55 kd tumor necrosis factor receptor is resistant to endotoxic shock, yet succumb to L. monocytogenes infection. *Cell* 73: 457–467.

18. Lotz M, Ebert S, Esselmann H, et al. (2005) Amyloid beta peptide 1–40 enhances the action of Toll-like receptor-2 and -4 agonists but antagonizes Toll-like receptor-9-induced inflammation in primary mouse microglial cell cultures. *J Neurochem* 94: 289–298.

19. Jekabson A, Mander P, Tickler A, et al. (2006) Fibrillar beta-amyloid peptide Abeta1-40 activates microglial proliferation via stimulating TNF-alpha release and H2O2 derived from NADPH oxidase: a cell culture study. *J Neuroinflammation* 3: 24.

20. Walter S, Letiembre M, Liu Y, et al. (2007) Role of the toll-like receptor 4 in neuroinflammation in Alzheimer’s disease. *Cell Physiol Biochem* 20: 947–956.

21. Clark IA, Alleva LM, Vissel B (2010) The roles of TNF in brain dysfunction and disease. *Pharmacol Ther* 128: 519–548.

22. Perry SW, Dewhuerst S, Bellizzi MJ, et al. (2002) Tumor necrosis factor-alpha in normal and diseased brain: Conflicting effects via intraneuronal receptor crosstalk? *J Neurovirol* 8: 611–624.

23. Beattie EC, Stellwagen D, Morishita W, et al. (2002) Control of synaptic strength by glial TNF alpha. *Science* 295: 2282–2285.

24. Kaneko M, Stellwagen D, Malenka RC, et al. (2008) Tumor necrosis factor-alpha mediates one component of competitive, experience-dependent plasticity in developing visual cortex. *Neuron* 58: 673–680.
25. Santello M, Bezzi P, Volterra A (2011) TNFα controls glutamatergic gliotransmission in the hippocampal dentate gyrus. *Neuron* 69: 988–1001.
26. Olmos G, Lladó J (2014) Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. *Mediators Inflamm* 2014: 861231.
27. Albensi BC, Mattson MP (2000) Evidence for the involvement of TNF and NF-κB in hippocampal synaptic plasticity. *Synapse* 35: 151–159.
28. Montgomery SL, Bowers WJ (2012) Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system. *J Neuroimmune Pharmacol* 7: 42–59.
29. Block ML, Hong JS (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. *Prog Neurobiol* 76: 77–98.
30. Colombo E, Farina C (2016) Astrocytes: key regulators of neuroinflammation. *Trends Immunol* 37: 608–620.
31. Deng Y, Xie D, Fang M, et al. (2014) Astrocyte-derived proinflammatory cytokines induce hypomyelination in the periventricular white matter in the hypoxic neonatal brain. *PLoS One* 9: e87420.
32. Choi SS, Lee HJ, Lim I, et al. (2014) Human astrocytes: secretome profiles of cytokines and chemokines. *PLoS One* 9: e92325.
33. Haseloff RF, Blasig IE, Bauer HC, et al. (2005) In search of the astrocytic factor(s) modulating blood-brain barrier functions in brain capillary endothelial cells in vitro. *Cell Mol Neurobiol* 25: 25–39.
34. Hailer NP, Wirjatijasa F, Roser N, et al. (2001) Astrocytic factors protect neuronal integrity and reduce microglial activation in an in vitro model of N-methyl-D-aspartate-induced excitotoxic injury in organotypic hippocampal slice cultures. *Eur J Neurosci* 14: 315–326.
35. Tae HJ, Kang IJ, Lee TK, et al. (2017) Neuronal injury and tumor necrosis factor-alpha immunoreactivity in the rat hippocampus in the early period of asphyxia-induced cardiac arrest under normothermia. *Neural Regen Res* 12: 2007–2013.
36. Bell JM, Breiding MJ, DePadilla L (2017) CDC’s efforts to improve traumatic brain injury surveillance. *J Safety Res* 62: 253–256.
37. Rodney T, Osier N, Gill J (2018) Pro- and anti-inflammatory biomarkers and traumatic brain injury outcomes: A review. *Cytokine* 110: 248–256.
38. Liu Y, Zhou LJ, Wang J, et al. (2017) TNF-α differentially regulates synaptic plasticity in the hippocampus and spinal cord by microglia-dependent mechanisms after peripheral nerve injury. *J Neurosci* 37: 871–881.
39. Hu X, Xu MX, Zhou H, et al. (2020) Tumor necrosis factor-alpha aggravates gliosis and inflammation of activated retinal Müller cells. *Biochem Biophys Res Commun* 531: 383–389.
40. Kim M, Jung K, Ko Y, et al. (2020) TNF-α pretreatment improves the survival and function of transplanted human neural progenitor cells following hypoxic-ischemic brain injury. *Cells* 9: 1195.
41. Botchkina GI, Meistrell ME, Botchkina IL, et al. (1997) Expression of TNF and TNF receptors (p55 and p75) in the rat brain after focal cerebral ischemia. *Mol Med* 3: 765–781.
42. Doll DN, Rellick SL, Barr TL, et al. (2015) Rapid mitochondrial dysfunction mediates TNF-alpha-induced neurotoxicity. *J Neurochem* 132: 443–451.
43. George FK, Paxinos G (2019) *Paxinos and Franklin’s the Mouse Brain in Stereotaxic Coordinates*, Compact, 5 th Edition, Academic Press.
44. Sugimura K, Ohno T, Fukuda S, et al. (1990) Tumor growth inhibitory activity of a lymphocyte blastogenesis inhibitory factor. Cancer Res 50: 345–349.
45. Abd-El-Basset EM, Rao MS (2018) Dibutyryl cyclic adenosine monophosphate rescues the neurons from degeneration in stab wound and excitotoxic injury models. Front neurosci 12: 546.
46. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685.
47. Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76: 4350–4354.
48. Zhang L, Yue Y, Ouyang M, et al. (2017) The effects of IGF-1 on TNF-α-Treated DRG neurons by modulating ATF3 and GAP-43 expression via PI3K/Akt/S6K signaling pathway. Neurochem Res 42: 1403–1421.
49. Abd-El-Basset EM, Rao MS, Alsaqobi A (2020) Interferon-gamma and interleukin-1beta enhance the secretion of brain-derived neurotrophic factor and promotes the survival of cortical neurons in brain injury. Neurosci Insights 15: 2633105520947081.
50. Hong H, Kim BS, Im HI (2016) Pathophysiological role of neuroinflammation in neurodegenerative diseases and psychiatric disorders. Int Neuropsychol J 20: S2–S7.
51. Dexter DT, Jenner P (2013) Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 62: 132–144.
52. Gendelman HE, Folks DG (1999) Innate and acquired immunity in neurodegenerative disorders. J Leukoc Biol 65: 407–408.
53. Botchkina GI, Geimonen E, Bilof ML, et al. (1999) Loss of NF-kappaB activity during cerebral ischemia and TNF cytotoxicity. Mol Med 5: 372–381.
54. Saito K, Suyama K, Nishida K, et al. (1996) Early increases in TNF-alpha, IL-6 and IL-1 beta levels following transient cerebral ischemia in gerbil brain. Neurosci Lett 206: 149–152.
55. Chung IY, Benveniste EN (1990) Tumor necrosis factor-alpha production by astrocytes. Induction by lipopolysaccharide, IFN-γ, and IL-1β. J Immunol 144: 2999–3007.
56. Kim BW, Koppula S, Hong S, et al. (2013) Regulation of microglia activity by glaucocalyxin-A: attenuation of lipopolysaccharidestimulated neuroinflammation through NF-κB and p38 MAPK signaling pathways. PLoS One 8: e55792.
63. Zola H, Flego L, Weedon H (1993) Expression of membrane receptor for tumour necrosis factor on human blood lymphocytes. *Immunol Cell Biol* 71: 281–288.
64. Medler J, Wajant H (2019) Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target. *Expert Opin Ther Targets* 23: 295–307.
65. Borghi A, Verstrepen L, Beyaert R (2016) TRAF2 multitasking in TNF receptor-induced signaling to NF-κB, MAP kinases and cell death. *Biochem Pharmacol* 116: 1–10.
66. Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. *Nat Rev Immunol* 3: 745–756.
67. Santello M, Volterra A (2012) TNFα in synaptic function: switching gears. *Trends Neurosci* 35: 638–647.
68. Sternberg EM (1997) Neural-immune interactions in health and disease. *J Clin Invest* 100: 2641–2647.
69. Olmos G, Lladó J (2014) Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. *Mediators Inflamm* 2014: 861231.
70. Dougherty KD, Dreyfus CF, Black IB (2000) Brain-derived neurotrophic factor in astrocytes, oligodendrocytes, and microglia/macrophages after spinal cord injury. *Neurobiol Dis* 7: 574–585.
71. Baune BT, Wiede F, Braun A, et al. (2008) Cognitive dysfunction in mice deficient for TNF- and its receptors. *Am J Med Genet B Neuropsychiatr Genet* 147B: 1056–1064.
72. Rostworowski M, Balasingam V, Chabot S, et al. (1997) Astrogliosis in the neonatal and adult murine brain post-trauma: elevation of inflammatory cytokines and the lack of requirement for endogenous interferon-gamma. *J Neurosci* 17: 3664–3674.
73. Myer DJ, Gurkoff GG, Lee SM, et al. (2006) Essential protective roles of reactive astrocytes in traumatic brain injury. *Brain* 129: 2761–2772.
74. Colombo E, Farina C (2016) Astrocytes: key regulators of neuroinflammation. *Trends Immunol* 37: 608–620.
75. Toft-Hansen H, Füchtbauer L, Owens T (2011) Inhibition of reactive astrocytosis in established experimental autoimmune encephalomyelitis favors infiltration by myeloid cells over T cells and enhances severity of disease. *Glia* 59: 166–176.
76. Anderson MA, Burda JE, Ren Y, et al. (2016) Astrocyte scar formation aids central nervous system axon regeneration. *Nature* 532: 195–200.
77. Goshi N, Morgan RK, Lein PJ, et al. (2020) A primary neural cell culture model to study neuron, astrocyte, and microglia interactions in neuroinflammation. *J Neuroinflammation* 17: 155.
78. Dougherty KD, Dreyfus CF, Black IB (2000) Brain-derived neurotrophic factor in astrocytes, oligodendrocytes, and microglia/macrophages after spinal cord injury. *Neurobiol Dis* 7: 574–585.
79. Solito E, Sastre M (2012) Microglia function in Alzheimer’s disease. *Front Pharmacol* 3: 14.
80. Glezer I, Simard AR, Rivest S (2007) Neuroprotective role of the innate immune system by microglia. *Neuroscience* 147: 867–883.
81. Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. *Science* 308: 1314–1318.
82. Lehnardt S (2010) Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. *Glia* 58: 253–263.
83. Ulmann L, Hatcher JP, Hughes JP, et al. (2008) Up-regulation of P2X4 receptors in spinal microglia after peripheral nerve injury mediates BDNF release and neuropathic pain. *J Neurosci* 28: 11263–11268.
84. Coull JA, Beggs S, Boudreau D, et al. (2005) BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. *Nature* 438: 1017–1021.

85. Poyhonen S, Er S, Domansky A, et al. (2019) Effects of neurotrophic factors in glial cells in the central nervous system: expression and properties in neurodegeneration and injury. *Front Physiol* 10: 486.

86. Mattson MP, Meffert MK (2006) Roles for NF-kappaB in nerve cell survival, plasticity, and disease. *Cell Death Differ* 13: 852–860.

87. Hempstead BL (2002) The many faces of p75NTR. *Curr Opin Neurobiol* 12: 260–267.

88. Somoza R, Juri C, Baes M, et al. (2010) Intranigral transplantation of epigenetically induced BDNF-secreting human mesenchymal stem cells: implications for cell-based therapies in Parkinson’s disease. *Biol Blood Marrow Transplant* 16: 1530–1540.

89. Scharfman H, Goodman J, Macleod A, et al. (2005) Increased neurogenesis and the ectopic granule cells after intrahippocampal BDNF infusion in adult rats. *Exp Neurol* 192: 348–356.

© 2021 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)